Project Grant R43AG055208

The General Hospital Corporation (MGH) Research Management Division was awarded a $458,585 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop a method for detecting autoantibodies against beta-amyloid in serum as a potential biomarker for Alzheimer's disease (AD). The 2-year project aims to investigate the use of small molecule compounds called CRANAD-XS to differentially tune the binding between beta-amyloid and its...

This National Institute on Aging (NIA) project grant, awarded under CFDA 93.866 Aging Research, aims to develop and test self-assembling peptide nanofiber vaccines targeting amyloid-beta and tau proteins for the prevention and treatment of neurodegenerative disorders like Alzheimer's disease and frontotemporal dementia. The $574,474 award, with an initial duration of September 30, 2024 to May 31, 2029, is provided to The Washington University to conduct the following key activities: 1) assess...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $238,500.00 to the University of California, San Diego (UCSD) to develop a highly effective phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic targeting amyloid precursor protein (APP) for the treatment of Alzheimer's disease. The research aims to solve the...

The National Institute on Aging (NIA) awarded a $356,174 Project Grant (CFDA 93.866, Aging Research) to the Regents of the University of California, San Francisco (UCSF) to conduct in vivo testing of structure-based vaccine candidates targeting Alzheimer's disease. The goal is to determine the efficacy of an active immunization strategy in preserving cognitive and neural function by slowing the formation of amyloid-beta or paired-helical filaments in the brain. This will involve immunizing 5XFAD...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $810,596 to New York University School of Medicine to develop a novel chimeric antigen receptor (CAR) macrophage (MI) therapy for the treatment of Alzheimer's disease (AD). The key products to be delivered include: Optimizing the transdifferentiation of human induced pluripotent stem cells (hiPSCs) into self-sustainable macrophage/microglia (IMI) cells that can be engineered to express CARs...

The National Institute on Aging (NIA) awarded a $717,491 Project Grant under its Aging Research program (CFDA 93.866) to New York University (NYU) School of Medicine to develop single domain antibodies (sdAbs) that can detect and clear alpha-synuclein (αSyn) in animal models of synucleinopathies. The project aims to evaluate the in vivo imaging potential, clearance mechanisms, and therapeutic efficacy of these sdAbs targeting αSyn, a key protein involved in neurodegenerative diseases like Lewy...

The University of Texas Medical Branch at Galveston will research immunotherapy targeting tau aggregate polymorphs under a $4.02 million project grant from the National Institute on Aging's Aging Research program (CFDA 93.866). The three-year award will support determining the efficacy of four monoclonal antibodies in targeting disease-relevant tau oligomeric strains/polymorphs implicated in neurodegenerative tauopathies like Alzheimer's disease and frontotemporal lobar degeneration. Researchers...

This $506,451 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development of a targeted exosomal delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, including Alzheimer's disease. The primary recipient, 3P Biotechnologies, Inc., will optimize the delivery of siRNA targeting NF-kB using folic acid-functionalized exosomes and a novel trans-spinal administration route. This innovative approach aims...

This $499,441 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Acepre, LLC aims to develop a novel brain-targeted delivery system for N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The proposed research includes evaluating the toxicity and pharmacokinetic properties of TN-NAC in mice (Specific Aim 1) and testing the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model (Specific Aim 2). Successful completion of these...

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) totaling $374,000.00 aims to develop a novel hematopoietic stem cell-based chimeric antigen receptor (CAR) macrophage therapy to target amyloid-beta aggregates and reduce neuroinflammation in Alzheimer's disease. The two-phase project focuses on optimizing the CAR-macrophage therapy for in vitro efficacy against amyloid-beta and investigating its safety and central nervous system trafficking in vivo during...